Disease-modifying antirheumatic drugs improve cardiovascular autonomic neuropathy in psoriatic arthritis

Abstract

Background: Cardiovascular autonomic neuropathy (CAN) is a significant risk predictor for sudden cardiac death in autoimmune rheumatic diseases. As yet, there is no therapeutic treatment of CAN in psoriatic arthritis (PsA). Even now, the impact of the most commonly employed disease-modifying antirheumatic drug (DMARD) therapy on CAN in PsA is not known. Hence, we investigated the impact of DMARDs on CAN in PsA. Methods: In this prospective, cross-sectional study, 20 patients of PsA and 20 ageand sex-matched healthy controls were recruited. CAN was diagnosed by applying the five cardiovascular reflex tests according to Ewing. Parasympathetic dysfunction was established by performing three tests: heart-rate response to deep breathing, standing, and Valsalva tests. Sympathetic dysfunction was examined by applying two tests: blood pressure response to standing, and handgrip tests. Disease severity was assessed by the 28-joint-count disease activity score (DAS-28) and the disease activity score in psoriatic arthritis (DAPSA). Results: Cardiovascular reflex tests were impaired significantly among the PsA patients compared with well-matched healthy subjects (p < 0.05). Parasympathetic dysfunction was more prominent than sympathetic dysfunction. After 12 weeks treatment, parasympathetic dysfunction (heart rate response to deep breath and standing) significantly (p < 0.05) improved in patients with PsA, while there was no significant improvement in sympathetic function. Conclusion: These study results suggests parasympathetic autonomic dysfunction is more prominent than sympathetic dysfunction in PsA. Synthetic DMARDs improved parasympathetic dysfunction in PsA.

Fatigue in chronic liver disease: New insights and therapeutic approaches

“…45,46 Moreover, elevated systemic TNFα levels have also been linked to the development of autonomic nervous system dysfunction in animal models 47 and in patients. 48 These observations potentially implicate TNFα as an important link between chronic liver injury, sickness behaviours (including fatigue) and autonomic dysfunction. They also suggest that inhibition of peripheral TNFα production and/or activity in CLD may represent a novel approach for treating fatigue in patients with CLD, and therefore warrants future study.…”

7.7 the Effect of Marine N-3 Polyunsaturated Fatty Acids on Cardiac Autonomic and Hemodynamic Function in Patients With Psoriatic Arthritis: A Randomised, Double-Blind, Placebo-Controlled Trial

“…We hypothesized that intervention with n-3 PUFA would increase RR. Based on previous literature [33,34] and to achieve α = 0.05 and 1-β = 0.80 we needed a sample size with 63 subjects in each group.…”

“…In a small study with 20 patients with PsA, Syngle et al observed improvement in autonomic dysfunction after treatment with different synthetic DMARDs over 12 weeks [33]. However, no treatment strategy for cardiac autonomic dysfunction in PsA has yet been demonstrated.…”

Efficacy and safety of leflunomide in psoriatic arthritis treatment: A single‐arm meta‐analysis

“…Variable outcomes and tolerability were reported for DMARDs such as methotrexate (MTX), sulfasalazine, cyclosporin, and intramuscular gold . Leflunomide, also a DMARD, inhibits the synthesis of de novo pyrimidine, following which T cell activation and proliferation is suppressed.…”